Growing body of evidence suggests that patients with high-risk BCR should be managed with ARpI monotherapy. Side effects are manageable. the sooner the better ! Neil Shore Advanced Prostate Cancer Consensus Conference @APCCC24 OncoAlert

❓ Patients with rising PSA post-RP & PSAdt <1 y OR ISUP 4-5 and ≥1 risk factor : ➤ 37% panelists would WAIT for PSMA-PET ➤ What happened to salvage RT to prostate bed ? 🤔 Advanced Prostate Cancer Consensus Conference @APCCC24 OncoAlert

Very nice take on doublet vs triplet therapy in mHSPC patients by Nick James also on @Prof-Nick-James.bsky.social at Advanced Prostate Cancer Consensus Conference #APCCC24 #OncoAlert

Now more than ever, it is important to propose de-escalation strategies. EORTC 2238 "De-Escalate" will address the specific question of intermittent therapy in these mHSPC patients ! tombal silke gillessen Fabio Turco Advanced Prostate Cancer Consensus Conference EORTC OncoAlert

🤔 How to choose a 1st line therapy in mCRPC patients nowadays ? 🚨 ➤ Some excellent suggestions from Christopher Sweeney, MBBS at Advanced Prostate Cancer Consensus Conference OncoAlert #APCCC24

95% of Advanced Prostate Cancer Consensus Conference Panellists DO NOT recommend ARPI switch for mCRPC. Yet why do investigators (many of them Panellists) and FDA approve this as control arm for trials?? “Unethical” says GrumpyOncologist from the floor, as did Vinay Prasad MD MPH on GU Cast GU Cast | Urology podcast! #APCCC24

🚨 Excellent talk on germline testing in PC by Heather H. Cheng🚨 ✅ It matters for patients AND families ✅ Germline alt. are FREQUENT and have consequences for patients 🧬Tumor-only sequencing failed to detect > 20% of pathogenic variants ⚠ Advanced Prostate Cancer Consensus Conference OncoAlert #APCCC24

OH LA PHOTO

#NOVEMBREAUMASCULIN - Conférence de presse en cours pour présenter cette 2e édition du Mois de la Santé Masculine 🔵 Pr. Alexandre de La Taille #Santemasculine #BrisonsLesTabous 🚹

Congrats to Julien Van Damme GIZZI Marco for this nice poster #EMUC24 tombal

Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment. Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 Yohann Loriot Vérane Achard Julien Van Damme Guillaume Grs tombal

mHSPC patient with profound PSA response : panel would propose de-escalation therapy ! #EMUC2024 tombal silke gillessen Fabio Turco

Thank you #EMUC24 for giving me the opportunity to talk about the management of mCRPC patients

Check out our free 20-minute webinar with a multidisciplinary panel of experts discussing the most recent data from clinical trials, treatment (de)escalation, and the role of ultra-low PSA in #mHSPC Register for free at library.mirrorsmed.org/?utm_code=SoMe… Julien Van Damme OncoAlert #GU

🚨 Defining clinical response to neoadjuvant CT in bladder is crucial to offer bladder-sparing strategies in complete or near cplt responders ! EORTC Starbust-1 will launch soon Alex Masson-Lecomte EORTC Yohann Loriot tombal Vérane Achard Julien Van Damme sciencedirect.com/science/articl…

🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟 EORTC #STARBURST project 🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, Julien Van Damme,  Vérane Achard  , Laura S. Mertens, Robert Huddart💙, francesco soria, Lars Dyrskjøt, Yves Allory Institut Curie,